Neurocrine Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition adds a first-in-class rare disease therapy, VYKAT XR, to the portfolio, accelerating revenue growth and diversification. The $2.9B all-cash deal is expected to be accretive in 2026, with strong IP protection and a focus on U.S. market expansion.
-
Revenue grew 22% last year, driven by Ingrezza and CRENESSITY, with strong guidance for 2026 and ongoing sales force expansion. Multiple phase II/III readouts are expected in 2027, including neuropsychiatry and next-gen VMAT2 programs, while pricing and access remain stable amid regulatory changes.
-
Two approved products are fueling strong growth, with CRENESSITY’s rare disease launch among the top 10% historically and INGREZZA targeting nearly 10% annual growth. R&D investment remains high, supporting late-stage trials and new obesity initiatives, while financials show robust cash, no debt, and strong profitability.
-
Strong commercial momentum for INGREZZA and CRENESSITY underpins financial strength and growth, with both products expected to drive double-digit volume increases. R&D strategy targets CNS leadership, diversified modalities, and a robust obesity pipeline, with key data expected in 2026.
-
Momentum and diversification are driving growth, with CRENESSITY exceeding launch expectations and robust two-year clinical data supporting its use in CAH. The R&D engine is delivering a diversified pipeline, with key neuropsychiatry and endocrinology assets advancing toward major milestones in 2027.
Fiscal Year 2025
-
2025 saw 22% sales growth to $2.8B, led by INGREZZA and CRENESSITY, with strong cash flow and operating margins. INGREZZA is set for 10% growth in 2026, while CRENESSITY reached 10% CAH market penetration in its first year. Pipeline and sales force expansions support continued momentum.
-
Revised summary: A transformed R&D engine drives a diversified pipeline with major late-stage neuropsychiatry and endocrinology programs, including Osavampator for depression and Direclidine for schizophrenia, both showing strong efficacy and safety. The company aims for one new medicine every two years and is expanding into obesity with a novel CRF2 agonist.
-
Strong execution led to significant growth for Ingrezza and a successful Crinecerfont launch, with both products showing substantial market potential. Strategic focus remains on maximizing current assets, managing IRA impacts, and leveraging a growing sales force, while upcoming R&D efforts aim to drive future innovation.
-
Strong Q3 revenue growth and record new patient starts were driven by Ingrezza and a successful Crinecerfont launch. Expanded market access and strategic investments are fueling momentum, while a robust R&D pipeline targets steady innovation and long-term growth.
-
Q3 2025 saw 28% year-over-year sales growth, driven by record performance from INGREZZA and CRENESSITY, both supported by expanded sales teams. The company maintains a strong cash position, robust pipeline progress, and is preparing for IRA-related market changes.
-
The summit highlighted a strategic shift toward internal discovery, new modalities, and validated targets, with a diversified pipeline in CNS, psychiatry, endocrinology, and immunology. Key programs like NBI-770, osavampator, and NBI-568 are advancing, while commercial growth remains strong, supporting ambitions for leadership in neuroscience.
-
Strong commercial growth and robust R&D productivity are driving momentum, with Ingrezza and crinecerfont outperforming expectations. Strategic focus on resilience, pipeline expansion, and leveraging regulatory advantages positions the company for sustained growth through 2026 and beyond.
-
INGREZZA continues strong double-digit growth with expanded Medicare coverage, while CRENESSITY’s launch has exceeded expectations, especially among endocrinologists. The company is advancing key phase III programs and is well-positioned for future regulatory and market shifts.
-
CRENESSITY's launch exceeded expectations, driven by early education and strong reimbursement, while INGREZZA posted record revenues and improved access. The pipeline is advancing with multiple Phase 1–3 programs, and strategic focus remains on U.S. growth, diversification, and robust R&D.
-
Q2 2025 saw 17% year-over-year sales growth, led by INGREZZA and a strong CRENESSITY launch. Expanded Medicare coverage and strategic investments are driving record new patient starts and market share gains, while a robust pipeline advances with multiple phase III programs.
-
Strong launches for CRENESSITY and INGREZZA are driving robust growth, with CRENESSITY exceeding early adoption and reimbursement expectations. Two major phase III programs are advancing, and financial flexibility remains high, supporting continued expansion.
-
CRENESSITY's launch is off to a strong, measured start, with early sales exceeding expectations and a focus on pediatric uptake. The pipeline is advancing with multiple data readouts expected this year, while the company invests heavily in growth and maintains a competitive edge through innovation and targeted patient outreach.
-
Record new patient starts for INGREZZA and a strong CRENESSITY launch drove Q1 2025 results, with reaffirmed guidance and expanded Medicare access supporting future growth. Multiple phase III programs advanced, and the company maintains a robust cash position.
-
2024 guidance for Ingrezza remains strong despite Q1 headwinds, with recovery and growth expected later in the year. Crinecerfont's launch is progressing well, with gradual uptake anticipated. Key pipeline programs, including AMPA potentiator and muscarinic agents, are advancing, with major data disclosures planned for an R&D event.
-
Ingrezza continues to drive strong sales, but faces increased payer hurdles and competition, prompting strategic focus on patient access and salesforce expansion. The newly approved Chronicity is set for a measured U.S. launch, with pipeline and R&D efforts advancing in neuroscience.
-
A robust pipeline and two blockbuster medicines, Ingrezza and CRENESSITY, anchor growth, with CRENESSITY’s launch showing strong early adoption and broad access. Despite Q1 headwinds from market dynamics and competitive pressures, investments in sales force and new data are expected to drive acceleration in the remainder of 2024.
-
Leadership outlined a strategy focused on sustained growth, R&D transformation, and commercial execution. Ingrezza and newly launched Crenessity drive financial strength, while a diversified pipeline and significant 2025 investments support long-term innovation. Less than 15% of TD patients are treated, highlighting growth potential.
Fiscal Year 2024
-
Record 2024 sales growth was led by Ingrezza, with 2025 guidance reflecting moderated but continued expansion amid increased competition and payer complexity. Crinecerfont's launch is off to a promising start, though early revenues will be limited by reimbursement timing.
-
Leadership transition emphasizes continuity and growth, with Ingrezza and crinecerfont as key drivers. Pipeline advances include two phase 3 programs, while commercial strategies focus on expanding awareness and prescriber reach. Manufacturing and regulatory risks are actively managed.
-
Crinecerfont is poised for early 2025 launch as a first-in-class CAH therapy, with strong demand expected from pediatric and female patients and initial adoption at Centers of Excellence. Ingrezza continues robust growth, supported by sales force expansion and updated market estimates, while the pipeline advances with promising MDD and schizophrenia programs.
-
Management highlighted strong growth for Ingrezza, with 25% year-over-year sales increase and a raised annual revenue outlook. The pipeline includes two NDAs for crinecerfont, a robust muscarinic portfolio, and next-gen VMAT2 inhibitors targeting new indications. Significant market opportunity remains, with 85% of TD patients untreated.
-
Leaders discussed navigating regulatory uncertainty, the upcoming crinecerfont launch for CAH, and ongoing Ingrezza growth. Strategic investments in R&D and lessons from recent clinical trials are shaping future neuroscience pipeline plans.
-
Strong Q3 revenue and raised 2024 guidance reflect robust demand in key markets. Crinecerfont is poised for launch in early 2025, with additional late-stage pipeline assets advancing. Recent $300M share buyback underscores financial strength and commitment to shareholder value.
-
Q3 saw robust INGREZZA sales and raised guidance, with strong demand and expanded market reach. Crinecerfont is on track for year-end approval, and a $300M share repurchase was authorized. R&D investment will increase in 2025, and pipeline prioritization continues.
-
Strong revenue growth is driven by Ingrezza and a potential 2025 launch of crinecerfont, while the pipeline advances with robust Phase II data for NBI-568 in schizophrenia and NBI-1065845 in depression. The company is shifting toward internal innovation and multi-modality R&D.
-
Leadership transition sets the stage for a new growth phase, with Ingrezza driving strong revenue and further expansion in psychiatry and long-term care. Crinecerfont and late-stage pipeline assets are positioned for future launches, supported by increased SG&A and R&D investment.
-
Leadership transition will focus on sustaining growth through a diversified pipeline and strong financials. INGREZZA and crinecerfont anchor revenue, while muscarinic and DAAO inhibitor programs advance. Multiple late-stage trials and data readouts are expected in 2025.
-
The conference highlighted a neuroscience-focused pipeline with strong growth in both commercial and R&D areas, including a promising muscarinic program for schizophrenia and a shift toward biologics and gene therapies. Leadership transition and a diversified, sustainable portfolio position the company for continued expansion.
-
A phase II study of NBI-568, a selective M4 agonist, in schizophrenia showed significant efficacy at 20 mg once daily, with robust safety and tolerability. The results support phase III advancement and highlight differentiation from other muscarinic agents.
-
Leadership transition is underway with a focus on culture and pipeline execution. INGREZZA continues robust growth, supported by sales force expansion and new patient starts, while crinecerfont and several neuropsychiatric candidates approach key regulatory and clinical milestones.
-
Q2 saw 32% year-over-year INGREZZA sales growth, leading to raised 2024 guidance. Crinecerfont received FDA priority review, and the pipeline advanced with positive NBI-845 data and new phase I entries. Financial flexibility supports continued investment in growth.
-
Leadership transition ensures strategic continuity as the company targets further growth for INGREZZA, expands its sales force, and advances a robust pipeline including crinecerfont and muscarinic assets. Key data readouts and potential product launches are expected in 2024–2025.
-
Leadership transition is underway with a smooth handoff to an internal successor, while the company advances a multi-product pipeline and maintains a strong financial outlook. Muscarinic and crinecerfont programs show promising clinical progress, and business development remains focused on organic growth.